Highly Penetrant Myeloproliferative Disease in the Ts65Dn Mouse Model of Down Syndrome

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2007 Sep 29

PMID 17901249

Citations 63

Authors

Gina Kirsammer

Sarah Jilani

Hui Liu

Elizabeth Davis

Sandeep Gurbuxani

Michelle M Le Beau

John D Crispino

Affiliations

Soon will be listed here.

Abstract

Children with Down syndrome (DS) display macrocytosis, thrombocytosis, and a 500-fold increased risk of developing megakaryocytic leukemia; however, the specific effects of trisomy 21 on hematopoiesis remain poorly defined. To study this question, we analyzed blood cell development in the Ts65Dn mouse model of DS. Ts65Dn mice are trisomic for 104 orthologs of Hsa21 genes and are the most widely used mouse model for DS. We discovered that Ts65Dn mice display persistent macrocytosis and develop a myeloproliferative disease (MPD) characterized by profound thrombocytosis, megakaryocyte hyperplasia, dysplastic megakaryocyte morphology, and myelofibrosis. In addition, these animals bear distorted hematopoietic stem and myeloid progenitor cell compartments compared with euploid control littermates. Of the 104 trisomic genes in Ts65Dn mice, Aml1/Runx1 attracts considerable attention as a candidate oncogene in DS-acute megakaryoblastic leukemia (DS-AMKL). To determine whether trisomy for Aml1/Runx1 is essential for MPD, we restored disomy at the Aml1/Runx1 locus in the Ts65Dn strain. Surprisingly, trisomy for Aml1/Runx1 is not required for megakaryocyte hyperplasia and myelofibrosis, suggesting that trisomy for one or more of the remaining genes can promote this disease. Our studies demonstrate the potential of DS mouse models to improve our understanding of chromosome 21 gene dosage effects in human hematologic malignancies.

Citing Articles

Down syndrome-associated leukaemias: current evidence and challenges.

Mason N, Cahill H, Diamond Y, McCleary K, Kotecha R, Marshall G Ther Adv Hematol. 2024; 15:20406207241257901.

PMID: 39050114 PMC: 11268035. DOI: 10.1177/20406207241257901.

Breathing and Oxygen Carrying Capacity in Ts65Dn and Down Syndrome.

DeRuisseau L, Receno C, Cunningham C, Bates M, Goodell M, Liang C Function (Oxf). 2023; 4(6):zqad058.

PMID: 37954975 PMC: 10634617. DOI: 10.1093/function/zqad058.

Synergistic roles of DYRK1A and GATA1 in trisomy 21 megakaryopoiesis.

Sit Y, Takasaki K, An H, Xiao Y, Hurtz C, Gearhart P JCI Insight. 2023; 8(23).

PMID: 37906251 PMC: 10895998. DOI: 10.1172/jci.insight.172851.

RUN(X) out of blood: emerging RUNX1 functions beyond hematopoiesis and links to Down syndrome.

Rozen E, Ozeroff C, Allen M Hum Genomics. 2023; 17(1):83.

PMID: 37670378 PMC: 10481493. DOI: 10.1186/s40246-023-00531-2.

Dissection of a Down syndrome-associated trisomy to separate the gene dosage-dependent and -independent effects of an extra chromosome.

Xing Z, Li Y, Cortes-Gomez E, Jiang X, Gao S, Pao A Hum Mol Genet. 2023; 32(13):2205-2218.

PMID: 37014740 PMC: 10281752. DOI: 10.1093/hmg/ddad056.

References

Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-61. DOI: 10.1016/S0140-6736(05)71142-9. View

James C, Ugo V, Le Couedic J, Staerk J, Delhommeau F, Lacout C . A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434(7037):1144-8. DOI: 10.1038/nature03546. View

Li Z, Godinho F, Klusmann J, Garriga-Canut M, Yu C, Orkin S . Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet. 2005; 37(6):613-9. DOI: 10.1038/ng1566. View

Richtsmeier J, Baxter L, Reeves R . Parallels of craniofacial maldevelopment in Down syndrome and Ts65Dn mice. Dev Dyn. 2000; 217(2):137-45. DOI: 10.1002/(SICI)1097-0177(200002)217:2<137::AID-DVDY1>3.0.CO;2-N. View

Rainis L, Toki T, Pimanda J, Rosenthal E, Machol K, Strehl S . The proto-oncogene ERG in megakaryoblastic leukemias. Cancer Res. 2005; 65(17):7596-602. DOI: 10.1158/0008-5472.CAN-05-0147. View

Jamieson C, Ailles L, Dylla S, Muijtjens M, Jones C, Zehnder J . Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004; 351(7):657-67. DOI: 10.1056/NEJMoa040258. View

Rowley J . The Philadelphia chromosome translocation. A paradigm for understanding leukemia. Cancer. 1990; 65(10):2178-84. DOI: 10.1002/1097-0142(19900515)65:10<2178::aid-cncr2820651004>3.0.co;2-#. View

Hollanda L, Lima C, Cunha A, Albuquerque D, Vassallo J, Ozelo M . An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nat Genet. 2006; 38(7):807-12. DOI: 10.1038/ng1825. View

Jablonska B, Ford D, Trisler D, Pessac B . The growth capacity of bone marrow CD34 positive cells in culture is drastically reduced in a murine model of Down syndrome. C R Biol. 2006; 329(9):726-32. DOI: 10.1016/j.crvi.2006.06.004. View

10.

Xu G, Nagano M, Kanezaki R, Toki T, Hayashi Y, Taketani T . Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood. 2003; 102(8):2960-8. DOI: 10.1182/blood-2003-02-0390. View

11.

Groet J, McElwaine S, Spinelli M, Rinaldi A, Burtscher I, Mulligan C . Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder. Lancet. 2003; 361(9369):1617-20. DOI: 10.1016/S0140-6736(03)13266-7. View

12.

Lange B . The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol. 2000; 110(3):512-24. DOI: 10.1046/j.1365-2141.2000.02027.x. View

13.

de Hingh Y, van der Vossen P, Gemen E, Mulder A, Hop W, Brus F . Intrinsic abnormalities of lymphocyte counts in children with down syndrome. J Pediatr. 2005; 147(6):744-7. DOI: 10.1016/j.jpeds.2005.07.022. View

14.

Reeves R, Irving N, Moran T, WOHN A, Kitt C, Sisodia S . A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet. 1995; 11(2):177-84. DOI: 10.1038/ng1095-177. View

15.

Rainis L, Bercovich D, Strehl S, Teigler-Schlegel A, Stark B, Trka J . Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood. 2003; 102(3):981-6. DOI: 10.1182/blood-2002-11-3599. View

16.

Bourquin J, Subramanian A, Langebrake C, Reinhardt D, Bernard O, Ballerini P . Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci U S A. 2006; 103(9):3339-44. PMC: 1413912. DOI: 10.1073/pnas.0511150103. View

17.

Kivivuori S, Rajantie J, Siimes M . Peripheral blood cell counts in infants with Down's syndrome. Clin Genet. 1996; 49(1):15-9. DOI: 10.1111/j.1399-0004.1996.tb04318.x. View

18.

Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz S . Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005; 280(24):22788-92. PMC: 1201515. DOI: 10.1074/jbc.C500138200. View

19.

Taub J, Mundschau G, Ge Y, Poulik J, Qureshi F, Jensen T . Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. Blood. 2004; 104(5):1588-9. DOI: 10.1182/blood-2004-04-1563. View

20.

Campbell P, Green A . The myeloproliferative disorders. N Engl J Med. 2006; 355(23):2452-66. DOI: 10.1056/NEJMra063728. View